The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators |
Type de publication | Journal Article |
Year of Publication | 2016 |
Auteurs | Benchekroun M, Romero A, Egea J, Leon R, Michalska P, Buendia I, Jimeno MLuisa, Jun D, Janockova J, Sepsova V, Soukup O, Bautista-Aguilera OM, Refouvelet B, Ouari O, Marco-Contelles J, Ismaili L |
Journal | JOURNAL OF MEDICINAL CHEMISTRY |
Volume | 59 |
Pagination | 9967-9973 |
Date Published | NOV 10 |
Type of Article | Article |
ISSN | 0022-2623 |
Résumé | Novel multifunctional tacrines for Alzheimer's disease were obtained by Ugi-reaction between ferulic (or lipoic acid), a melatonin-like isocyanide, formaldehyde, and tacrine derivatives, according to the antioxidant additive approach in order to modulate the oxidative stress as therapeutic strategy. Compound 5c has been identified as a promising permeable agent showing excellent antioxidant properties, strong cholinesterase inhibitory activity, less hepatotoxicity than tacrine, and the best neuroprotective capacity, being able to significantly activate the Nrf2 transcriptional pathway. |
DOI | 10.1021/acs.jmedchem.6b01178 |